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Abstract: Advances in manufacturing processes provide the ability for the high throughput
production of liposomes containing a range of moieties, from small molecules to large biologicals
(including proteins and nucleic acids for prophylactic and therapeutic applications). Whilst rapid
quantification methods for small molecules are generally well established, the ability to rapidly
quantify liposomal entrapment of proteins is limited. Indeed, most standard protein quantification
techniques (including the BCA assay and Reverse phase-high performance liquid chromatography
(RP-HPLC)) measure protein encapsulation indirectly, by measuring the amount of non-incorporated
drug, and subtracting from the initial amount of protein added. However, this can give inaccurate and
misrepresentative results. To address this, we have developed a range of methods to directly quantify
protein entrapment within liposomes. The encapsulation efficiency within neutral, anionic and
cationic liposome formulations was determined by three techniques; BCA assay, RP-HPLC and HPLC
coupled to an evaporative light scattering detector, (HPLC-ELSD). All three methods are reliable for
the quantification of protein, with linear responses and correlation coefficients of 0.99, and LOQ for
all three methods being less than 10 µg/mL. Here within, we provide three methods for the rapid
and robust quantification of protein loading within liposomal (and other bilayer) vesicle systems.
Keywords:microfluidics; liposome; solubilisation; protein quantification; reverse-phase-high performance
liquid chromatography (RP-HPLC); HPLC-evaporative light scattering detector (HPLC-ELSD)
1. Introduction
Liposomes are well recognised for their efficacy in drug delivery, with a growing interest within
the field of vaccine development [1,2]. The delivery and appropriate targeting of subunit antigens
or highly purified protein recombinants as vaccines can be enhanced by incorporating antigens with
a suitable delivery system, particularly for routes of administration that pose challenges for the
stability of the proteins such as the oral, intranasal or pulmonary [3]. Liposomes are a well-established
drug delivery system, and their use as a delivery vehicle for proteins and peptides, in particular
for the delivery of vaccines, is widely reported [4–6]. However, until recently, the manufacture
of liposomal delivery systems has presented a notable barrier in the translation from bench to
product [7]. For example, marketed products, such as the Doxil/Caelyx liposomal formulation,
requires time consuming, multi-step procedures [8], which incurs high economic costs. However,
with an increased interest surrounding novel technologies that use microfluidics to produce liposomal
vesicles [7,9–11], industrial scale production of liposomes is now much more applicable. Given this
rise in high-throughput manufacturing techniques for liposomal delivery vehicles, as well as their
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growing use as vaccine delivery systems, there remains a need for rapid analytical techniques for the
quantification of protein loading within liposomal delivery systems [12].
Currently, there are a range of techniques available to quantify the protein loading capacities of
drug delivery systems (Table 1) [13–19]. Protein quantification techniques can include bicinchoninic
acid assay (BCA), variations of high-performance liquid-based chromatography (HPLC) and the use of
fluorescently labelled or radio-chemically labelled proteins. Less novel chemical analytical techniques
also include the use of the Kjeldahl method to determine the nitrogen content in organic substances.
The BCA assay uses peptide bonds in the protein reducing Cu2+ to Cu+ at a rate proportional to
the amount of protein present. The bicinchoninic acid reagent then binds with the Cu+, forming a
complex which absorbs light around 562 nm wavelength, allowing a direct correlation between protein
concentration within a sample and absorbance to be made [20]. Whilst the BCA assay can be utilised
for large sample screening given the microplate setup, limitations still exist involving interference from
a range of agents, including lipids. Other high throughput methods, such as HPLC, can be used to
quantify protein, with many variations of HPLC techniques available [21,22], including reverse phase
(RP) HPLC, which is commonly used for protein analysis. Although RP-HPLC and the BCA assay
are readily available to most analytical laboratories [23], the use of HPLC-evaporative light scattering
detector (HPLC-ELSD) is a good alternative for when the active pharmaceutical ingredient does not
have a chromophore, or for impurity analysis [24]. Previous papers from our group have shown the
ability to quantify lipids using an HPLC-ELSD system [25], and it is reported to detect analytes at high
sensitivity rates [26].
However, despite these available methods, routinely the encapsulation efficiencywithin liposomes
is determined indirectly by measuring the free un-encapsulated protein following separation via, i.e.,
centrifugation, dialysis or chromatography. This presentsmajor issues, given it involves the assumption
that all of the protein not measured is associated with the delivery vesicles and assumes mass balance is
achieved. Therefore, to address this and better support the formulation and development of liposomal
protein delivery systems, we have compared the ability of three techniques (BCA, RP-HPLC and
HPLC-ELSD) to directly quantify encapsulated protein within liposomal delivery vesicles.
2. Materials and Methods
2.1. Materials
The lipids 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dioleoyl-3-trimethylammonium-
propane (DOTAP) and L-α-phosphatidylserine (Brain PS, Porcine) were all purchased from Avanti
Polar Lipids Inc., Alabaster, AL, US. Cholesterol (cholesterol), Ovalbumin (OVA), trifluoroacetic acid
and D9777-100ft dialysis tubing cellulose were purchased from Sigma Aldrich Company Ltd., Poole,
UK. A Jupiter column (C18 (300 Å), 5 µm, dimensions 4.60 × 150 mm pore size 100 Å) was used in
HPLC and purchased from Phenomenex., Macclesfield, UK. The Pierce™ micro BCA Protein Assay kit,
HPLC grade methanol and 2-propanol were purchased from Fisher Scientific, Loughborough, England,
UK. All water and solvents used were HPLC grade.
2.2. Methods
2.2.1. Protein Quantification Techniques
An RP-HPLC method was developed using a universal UV-HPLC by Hewlitt Packard 1100 Series
(Santa Clara, CA, USA) to quantify the model antigen ovalbumin (OVA). All samples were run at
280 nm, using a C18 column (i.d. 150 × 4.6 mm) from Phenomenex (Macclesfield, UK). A 1 mL/min
flow rate was used with a twenty-minute elution gradient, composed of solvent A (0.1% TFA in water)
and solvent B (100% methanol). During the first ten minutes, the gradient was 100:0 (A:B), at 10.1 min
0:100 (A:B) and then back to the initial gradient of 100:0 (A:B) from 15.1 to 20 min. The injection volume
for the sample was 20 µL.
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Table 1. Examples of methods used to quantify protein loading in liposomal formulations.
Protein Loaded Liposome Formulation
Liposome Production
Technique
Method of Protein
Quantification
Reference
Bovine Serum
Albumin
Dipalymitol phosphatidylcholine, cholesterol
and didodecyldimethyl ammonium bromide. Lipid film hydration BCA Assay [13]
Ovalbumin Phospholipid S and cholesterol. Lipid film hydration BCA Assay [15]
Hepatitis B core
peptide
(HBCAg126-140)
Dipalymitol phosphatidylcholine, cholesterol
and dipalmitoyl phosphatidylglycerol.
Modified Freeze-Thaw
method RP-HPLC [16]
Superoxide
Dismutase
A range of cationic liposome systems were
tested. Lipid film hydration HPLC [17]
Bovine Serum
Albumin
Phosphatidylcholine and cholesterol based
formulation. Lipid film hydration Kjedahl Method [27]
Acetylcholinesterase Egg phosphatidylcholine based formulation. Lipid film hydration Acetylcholinesteraseactivity [28]
Insulin Hydrogenated Phosphatidylcholine andcholesterol. Lipid film hydration BCA Assay [29]
Protein corona PEGylated Doxorubicin-encapsulatedLiposomes Lipid film hydration BCA Assay [30]
Epidermal Growth
Factor (EGF) Dimethyldioctadecylammonium bromide Lipid film hydration HPLC [31]
Emtansine
(antibody–drug
conjugate)
Distearoylphosphatidylethanolamine-poly,
1-2-dioleoyl-sn-glycero-3-phoshoeethanolamine Lipid film hydration HPLC [32]
BCA: bicinchoninic acid assay; RP-HPLC: reverse –phase high performance liquid chromatography; HPLC: high
performance liquid chromatography.
For ELSD, HPLC was used in conjunction with a SEDEX 90LT evaporative light scattering
detector (ELSD) (Sedex sedere, Alfortville, France) for OVA quantification. A Jupiter A100 column
was used to detect the OVA protein. The flow rate used was 1 mL/min, with a gain of 8 and an OVA
peak appearing at 11.8 min. A standard calibration curve for OVA was established using various
concentrations; the amount of encapsulated OVA in liposomes was calculated using the peak area of
the sample in relation to the standards.
Protein quantification using Micro BCA (Pierce™ BCA Protein Assay Kit, Sigma Aldrich, Poole,
UK) protein assay was carried out under manufacturer’s instructions. Briefly, samples were incubated
up to 2 h at 35 ◦C, with 150 µL of sample + 150 µL of the working reagent. Absorbance was then
measured at 562 nm using a Bio-rad 680 microplate reader.
2.2.2. Liposome Manufacture and Purification
The preparation of liposomes by microfluidics was conducted on the Nanoasemblr® Benchtop
system from Precision Nanosystems. Selected lipids were dissolved in methanol at specific concentrations
(ranging primarily between 0.1–4 mg/mL total lipid) and injected through one of the two inlets on
the microfluidics herringbone micromixer chip, whilst the aqueous phase, PBS; pH 7.3 ± 0.2 or TRIS
(pH 7.4) is injected into the second inlet. A flow rate ratio (FRR; the ratio between the aqueous phase
and the lipid phase) of 3:1 was selected for neutral and anionic liposomal formulations, while 1:1
FRR was selected for cationic formulations. Total flow rates (TFR) (the speed at which the two inlets
are injected through the chip) between 10–15 mL/min were selected. For OVA loaded liposomal
samples, OVA is added in the aqueous phase at specific concentrations and the same principles for the
production of empty liposomes was followed.
Following microfluidic production of liposomes, purification of solvent from the sample is
required. For “empty” liposomes, dialysis was conducted usingMw 14,000 Da membrane, where 1 mL
of the liposomal sample (0.1–4 mg/mL) was loaded and sealed, before being submerged in 200 mL of
equivalent buffer for 1 h at room temperature under gentle agitation via magnetic stirring. The dialysis
membrane was pre-treated in a solution of 2% sodium bicarbonate, 1 mM EDTA and 1 L of ultrapure
water at 80 ◦C for 2 h under magnetic stirring. The membrane was then rinsed with water to remove
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any trace of pre-treated solution and stored in 20% ethanol (EtOH). For purification of OVA loaded
liposomes, samples were purified using Krosflo Research Iii tangential flow filtration system fitted
with an mPES (modified polyethersulfone) column with a pore size of 750 kDa to support effective
separation of the protein (OVA; 45 kDa) and the liposomes. Liposomal samples were circulated
through the column and purified through difiltration, with fresh PBS being added at the same rate as
the permeate leaving the column.
2.2.3. Method Validation
Linearity was assessed by the design of calibration curves across ovalbumin concentrations.
The signal output (Area (mAU), Area (mV) and absorbance for RP-HPLC, ELSD-HPLC and BCA
respectively) was plotted against known concentrations to determine the equation of the straight line
and regression coefficient (R2).
Limit of detection (LOD) and limit of quantification (LOQ) were calculated using the following
Equations (1) and (2). The standard deviation of the response (σ), divided by the gradient of the slope,
multiplied by 3.3 or 10 (LOD and LOQ, respectively) [33,34].
LOD =
(
3.3× (
σ
S
)
)
(1)
LOQ =
(
10× (
σ
S
)
)
(2)
Accuracy (trueness) was calculated using the difference between theoretical and experimental
values, taken at three separate concentrations across the assay in triplicate using a low, medium and
high concentration value [22,33]. The accuracy can be defined as the closeness of agreement between
the mean and the accepted true value together with confidence values [33].
Accuracy =
(True Value−measured value)× 100
True Value
(3)
Intra-day Precision (Repeatability) is an expression of the closeness of values taken under the same
experimental conditions, over a short period of time (the same day). Inter-day Precision (Intermediate
Precision) was determined over 3–5 separate days. Results are expressed as %RSD using a minimum
of nine determinations (three concentrations: low, medium and high, three replicates of each).
% RSD =
(
Standard deviation
mean
)
× 100 (4)
2.2.4. Statistical Analysis
Results are represented as mean ± SD with n = 3 independent batches. ANOVA tests were used
to assess statistical significance (p value of less than 0.05), with a Bland and Altman method used to
assess the agreeability between the three quantification methods. The mean difference, along with the
standard deviation, was calculated with a 95% confidence interval.
3. Results
Calibration curves were generated using the micro BCA assay, RP-HPLC and HPLC-ELSD to
establish linearity (Figure 1), and the validation results from each process are summarised in Table 2.
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Figure 1. Ovalbumin calibration curves for three quantification techniques. The calibration curves for micro BCA (A–C) include: Intraday curves (A), Interday curves
(generated over 5 separate days) (B), alongside the average (C). Calibration curves were also generated for RP-ELSD (D–F), including: Intraday curves (D), Interday
curves (generated over 3 separate days) (E), as well as the average (F). The same was also generated for the HPLC-ELSD (G–I): Intraday curves (G), Interday curves
(H), and the average (I). Results represent the average of at least three replicate measurements ± standard deviation (SD).
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Table 2. A comparison of three protein quantification techniques; micro BCA, RP-HPLC, and HPLC-ELSD. For all three methods, the accuracy was determined at
three concentrations, while Intra-day and Inter-day precision was calculated across three different concentrations with %RSD shown. The LOD and LOQ were also
determined for the respective quantification techniques. Results represent the average of at least three replicate measurements ± standard deviation (SD).
Concentration R2 Equation Mean (SD) %RSD Accuracy LOD LOQ
(µg/mL) Intra-Day Inter-Day Intra-Day Inter-Day (%) (µg/mL) (µg/mL)
micro BCA
5 0.9985 y = 0.013x + 0.0178 4.89 (0.75) 4.48 (0.73) 4.40 2.26 95.32 ± 0.94 1.85 5.61
20 20.86 (1.84) 20.61 (1.46) 2.42 1.18 102.94 ± 1.85
35 35.5 (0.79) 35.1 (0.79) 1.76 0.38 100.63 ± 0.99
RP-HPLC
25 0.9925 y = 0.3658x + 0.2811 26.02 (1.82) 27.87 (1.26) 6.41 4.35 101.39 ± 0.10 2.43 7.37
200 193.15 (18.22) 185.25 (4.24) 9.32 2.28 94.53 ± 6.03
400 436.44 (9.08) 415.40 (5.00) 2.07 1.20 102.74 ± 3.45
HPLC-ELSD
100 0.9946 y = 75,410x −2 × 106 81.17 (3.33) 87.18 (6.93) 5.89 11.44 93.37 ± 4.41 0.77 2.33
200 203.32 (5.53) 215.08 (7.90) 3.09 4.19 102.31 ± 13.8
400 417.02 (5.57) 402.31 (36.95) 1.42 9.84 99.21 ± 5.59
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3.1. Ovalbumin Quantification via Micro BCA Assay
Calibration curves were generated by micro BCA analysis across a concentration range of
0.5–40 µg/mL (Figure 1A–C). A linear relationship was observed as expected (R2 values > 0.997), with
Figure 1A showing the intra-day repeatability, Figure 1B showing inter-day precision and Figure 1C
showing the average. The LOD and LOQ were 1.85 µg/mL and 5.61 µg/mL, respectively (Table 2).
Intra-day repeatability and inter-day precision (over five independent days) was calculated at low
(5 µg/mL), medium (20 µg/mL) and high (35 µg/mL) concentrations. At each concentration, the mean
value and the % RSD was calculated. At each concentration, both intra- and inter-day precision was
acceptable, with the %RSD being with ± 5% (Table 2). Accuracy was also calculated across the three
concentration ranges, with all determinations falling within an accepted range (95–105%; Table 2).
3.2. Ovalbumin Calibration Curves Using RP-HPLC
Using RP-HPLC, a gradient method was used to establish a calibration curve (from 5–400 µg/mL)
(Figure 1D–F). Again a linear relationship was observed ((R2 values > 0.987) with good intra-day
(Figure 1D) and inter-day (Figure 1E) reproducibility. Using this method, LOD and LOQ values
of 2.43 µg/mL and 7.37 µg/mL, respectively, were determined (Table 2). Intra-day repeatability
and inter-day precision (over five independent days) was calculated at low (25 µg/mL), medium
(200 µg/mL) and high (400 µg/mL) concentrations. At each concentration, the %RSD being with±10%
(Table 2). Accuracy was also calculated across the three concentration ranges, with all determinations
falling within an accepted range (95–105%; Table 2).
3.3. Ovalbumin Calibration Curves Using HPLC-ELSD
The ELSD was used together with the HPLC to determine if this technique was comparable to the
RP-HPLC method. As with the RP-HPLC method, a gradient elution method was used. Calibration
curves were established (using the concentration ranges 0–400 µg/mL; Figure 1G–I). Intra-day and
inter-day repeatability curves were again plotted (Figure 1G,H), with the regression coefficient greater
than 0.989 for all curves (Table 2). Using this method, the LOD was 0.77 µg/mL and LOQ was
2.33 µg/mL. Similar to RP-HPLC, the intra-day and inter-day precision was calculated at low, medium
and high concentrations (Table 2). Intra-day repeatability RSD values remained within the acceptance
criteria (at 5% RSD or below). With inter-day repeatability, the RSD values increased up to 11.44%
(Table 2). Accuracy of the assay across the concentrations remained within the acceptance criteria,
although at the lower concentration of 100 µg/mL the accuracy dropped to 93.37 ± 4.41%.
3.4. Liposome Solubilisation and Lipid Interactions
Given all three methods were shown to effectively quantify protein concentration, the next
step was to develop an extraction method for measuring protein within the liposomes and also
to consider interference from lipids within the formulation. In order to quantify the amount of
entrapped protein inside liposomes, solubilisation of the liposomes was required. To achieve this,
a previously reported and validated protocol using isopropanol (IPA):buffer (at a 50/50 v/v) was
adopted [35]. To investigate the impact of liposome interference, three formulations were selected.
A neutral liposomal formulation (DSPC:Chol), an anionic formulation (DSPC:Chol:PS) and the cationic
liposomal formulation (DSPC:Chol:DOTAP). The formulations were prepared by microfluidics at a
range of final lipid concentrations (0.1–4 mg/mL). In the case of RP-HPLC, the presence of lipids
does not interfere with the quantification of the OVA, but solubilisation of the liposomes is necessary,
and thus the IPA:buffer 50:50 v/v was adopted. Due to the nature of the ELSD, the encapsulated
OVA can be quantified without solubilisation of the liposomes, and the lipids do not interfere in
protein quantification. In the case of the BCA assay, solubilisation of the liposomes is required to
release the protein, and the presence of lipids also interferes with the assay. The results in Figure 2
show a gradual increase in absorbance for all three formulations as the concentration increases, with
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all three formulations showing high degrees of linearity (R2 > 0.96). A small gradient for all three
formulations can be observed, with lipid concentration having limited impact across the range tested
(Figure 2). However, the degree of interference varied with formulation, with the cationic liposomal
formulation showing the lowest increase over the concentration range tested, whilst the anionic and
neutral formulation resulted in higher levels of interference (Figure 2).

Figure 2. The effect of increasing liposome concentration on micro BCA absorbance with no ovalbumin
added. Three liposomal formulations were produced using microfluidics (FRR 3:1 and 1:1, TFR 10
mL/min), DSPC:Chol, DSPC:Chol:PS and DSPC:Chol:DOTAP and assessed for BCA absorbance
interference. Results represent the average of at least three replicate measurements ± standard
deviation (SD).
Lipid interference in bicinchoninic acid based assays has been previously shown by Kessler and
Fanestil [36]. Therefore, in order to determine whether OVA can be quantified in a linear manner
in the presence of liposomes, “empty” DSPC:Chol (10:5 wt/wt, 3:1 FRR, 10 mL/min) liposomes
were produced via microfluidics and then mixed with the OVA at a final concentration of 1 mg/mL.
Protein concentrations remained fixed as for OVA in water (Figure 1), and the resulting blanks for
subtraction consisted of liposomes in water with no OVA present. Figure 3 shows the intra-day
repeatability (3 replicates; Figure 3A), the inter-day repeatability (5 days; Figure 3B), and the average
of three calibration curves used generated for LOD and LOQ is shown in Figure 3C. All curves
generated R2 > 0.99, and despite the presence of liposomes in the samples, the LOD and LOQ values
following blank subtraction remained low (1.07 and 3.24 µg/mL, respectively), similar to the micro
BCA analysis of protein in water alone (Figure 1). Accuracy values were also within the accepted range
(102.8 ± 0.61, 99.44 ± 2.07 and 100.63 ± 2.59% at low, medium and high concentrations, respectively),
and intra-day and inter-day repeatability %RSD values of 5% and below were obtained for both
medium and high concentrations (Figure 3). Intra-day and inter-day precision resulted in a high %RSD
value for the lowest concentration of 5 µg/mL (11.29% and 9.67%, respectively); however, the 20
and 35 µg/mL values remained within the acceptance criteria (Figure 3). These results show that the
presence of protein outside of liposomes can be measured using the BCA assay if appropriate liposome
blanks are incorporated. This method could be used for the indirect quantification of protein loading,
however, as mentioned, this method is limited due to assumptions that no protein is lost during the
production process.
Pharmaceutics 2019, 11, 39 9 of 16

Figure 3. Ovalbumin calibration curves in water in the presence of liposomes (DSPC:Chol 10:5 wt/wt; at a fixed final concentration of 1 mg/mL). The LOD and LOQ
values were established using micro BCA, following empty liposome blank removal. Intraday curves were generated (A) within the same day, while Interday curves
were generated over 5 separate days (B) along with the average (C). Accuracy was determined at three concentrations, while Intra-day and Inter-day precision was
calculated across three different concentrations, with %RSD shown.
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Given the presence of lipid could be accommodated within the assay, the next stage was to
determine the protein entrapment efficiency following solubilisation to allow the direct quantification
of protein encapsulated within liposomes. Therefore, calibration curves were established (using the
same concentration ranges of 0–40 µg/mL) to determine whether linearity can be achieved in the
presence of solubilisation mixture and liposomes using micro BCA. Figure 4 shows the intra-day
repeatability (3 replicates; Figure 4A), the inter-day repeatability (5 days; Figure 4B), and the average
of three calibration curves used generated for LOD and LOQ is shown in Figure 4C. Again, all curves
resulted in regression coefficients greater than 0.98. With the presence of the solubilising agent, the
LOD and LOQ (2.36 and 7.14 µg/mL, respectively) was found to be higher than protein alone (Table 2).
Intra-day and inter-day repeatability RSD values for both medium and high concentrations remained
within the acceptance criteria (5% RSD or below), however, low concentrations of intra-day and
inter-day repeatability resulted in a calculated %RSD of 27.12% and 7.87%, respectively (Figure 4).
Accuracy of the assay at low, medium and high concentrations all remained within the acceptance
criteria. With the micro BCA assay, the manufacturers note that if interfering substances cannot be
purified, the sample can be diluted down to an acceptable level of interference. In the liposome
formulations tested here (and specifically the concentrations used), linearity could be maintained.
However, the addition of up to 5% SDS can also be considered if the lipid concentration is high within
the sample and a loss of linearity is observed.
3.5. Comparing the Analytical Techniques for the Quantification of OVA Loaded Liposomes
With all three methods established, the ability of the three analytical techniques (BCA assay,
RP-HPLC and HPLC-ELSD) to quantify entrapped OVA was analysed. Three liposomal formulations
containing DSPC lipid were investigated in triplicate (Figure 5). All three methods are able to quantify
the amount of OVA encapsulated by neutral DSPC:Chol liposomes (Figure 5), with the amount
calculated being between 52–56 µg/mL (represented by grey circles in Figure 5), with an encapsulation
efficiency of 34–38% (open circles). Similar reproducibility was shown with anionic (DSPC:Chol:PS)
and cationic (DSPC:Chol:DOTAP) formulations. However, with the cationic liposome formulation,
where the protein is electrostatically bound to the liposomal membranes, the micro-BCA assay gave
a broader range of encapsulation efficiencies (87–119%; mean 106 ± 12%; Figure 5) compared to the
HPLC based methods. In contrast, the efficiency measured using the RP-HPLC was 82 ± 3%, and with
HPLC-ELSD it was 80 ± 3%. Statistical analysis of the three techniques showed the results obtained
are not significantly different (p < 0.05), which confirms the agreeability between the three techniques.
Further analysis comparing the techniques was performed using the Bland and Altman plot analysis
(Figure 6). This is an alternative analytical approach; it is used to quantify the agreeability between
different methods by calculating the mean difference and identifying the limits of agreement [37].
All three formulations were added into the same figure for visual comparison, with the upper and
lower limits of agreement calculated as a whole. From Figure 6 there is no obvious bias, with all
formulation plots within the upper and lower limits of agreement. The neutral DSPC:Chol and anionic
DSPC:Chol:PS formulation plots are close to the mean, highlighting a good degree of agreeability
between the three methods. In comparison, the DSPC:Chol:DOTAP plots are more variable with a
wider distribution, which highlights the variability between the three cationic formulation batches (as
highlighted in Figure 5) rather than the analytical techniques used. As the OVA is adsorbed onto the
surface rather than encapsulated within, this may result in less effective solubilisation and release of
the protein from the formulation, leading to a greater degree of variability between the formulations
produced. Overall, the statistical results show the methods are comparable to one another, with all
three analytical techniques producing similar encapsulation results.
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
Figure 4. Ovalbumin calibration curves in water in the presence of liposomes (prepared as per Figure 3) and the addition of solubilisation mixture (50/50 v/v
IPA/water). The LOD and LOQ values were established using micro BCA. Intraday curves were generated (A) within the same day, while Interday curves were
generated over 5 separate days (B) along with the average (C). Accuracy was determined at three concentrations, while Intra-day and Inter-day precision was
calculated across three different concentrations with, %RSD shown.
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
ƺ
Figure 5. Comparative study between three protein quantification techniques, RP-HPLC, HPLC-ELSD
and BCA assay. All three liposomal formulations were made using microfluidics. The DSPC:Chol and
DSPC:Chol:PS formulations were made at a 3:1 FRR and 15 mL/min TFR (4 mg/mL initial lipid and
0.25 mg/mL initial ovalbumin concentration). The DSPC:Chol:DOTAP formulation was produced at a
1:1 FRR, and the ovalbumin was adsorbed onto the surface by passing pre-made DSPC:Chol:DOTAP
formulation through the microfluidics NanoAssemblr. All results were measured three times, with the
average encapsulation and ovalbumin loading calculated.

ƺ
Figure 6. Bland and Atlman plot analysis for the comparison of three analytical techniques. Plot
of differences between three analytical techniques (RP-HPLC, HPLC-ELSD and BCA assay) on the
y-axis, versus the mean of the three analytical techniques for the three formulations (DSPC:Chol,
DSPC:Chol:PS and DSPC:Chol:DOTAP). The calculated mean is −8.8 (horizontal solid line), with the
bias represented by the gap between the mean and the dashed lines. All formulations were measured
three times for the encapsulation efficiency, with each measurement plotted.
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4. Discussion
Whilst there are a range of analytical tools available to quantify protein concentration, the ability
of these methods to quantify protein loading within liposomes has received limited robustness testing.
Therefore, a deeper understanding of the advantages and limitations of these assays is necessary
for their effective use. During formulation development, small quantities of liposomes containing
protein are produced, with assays requiring a high degree of sensitivity for quantification. Initial
experimentation assessed the ability of three techniques (RP-HPLC, HPLC-ELSD, BCA assay) to
determine ovalbumin concentrations. All techniques showed high degrees of linearity over the protein
concentrations tested (R2 > 0.98) (Figure 1), with accuracy and precision values within ICH guidelines.
All three methods have the ability to detect and quantify protein at low concentrations, with LOD
values of less than 3 µg/mL and a LOQ values of between 2.33–7.37 µg/mL. The ELSD-HPLC method
is the most sensitive, with the lowest LOD (0.77 µg/mL) and LOQ (2.33 µg/mL) calculated. An
added feature of the ELSD-HPLC is the ability to change the gain (the sensitivity) of ELSD component.
This allows the system to be further optimised, making this system more versatile and easily adaptable
depending on specific needs.
As the liposomes are a mixture of lipids, cholesterol and protein, the quantification of protein
without interference from the lipid components or solubilisation is important. Whilst the lipids do not
interfere with the RP-HPLC and HPLC-ELSD techniques, interference is observed from lipids while
using BCA [36], resulting in higher absorbance values. To address this, we have developed a method to
accommodate and circumvent lipid background interference, and in the liposome concentration range
tested here, linearity was maintained. However, at much higher liposome concentrations the assay
could potentially lose its linear association between absorbance and protein concentration as a result of
the lipid interference. When attempting to analyse protein loading, it is crucial that relevant liposome
blanks are produced in order to accurately quantify the protein within the sample. However, based on
Figure 2, the background interference for a given liposome formulation at a given concentration can be
calculated. Therefore, when analysing a large number of samples with the same liposome concentration
and formulation, the BCA assay can be used as a valuable tool for high throughput screening.
In comparison, the HPLC techniques offer quick quantification time, in addition to having the
capacity to scale-up to larger quantities. Both RP-HPLC and HPLC-ELSD offer ease of quantification,
as the lipids do not interfere with the ovalbumin quantification. Previous results comparing HPLC
separation modes (including reverse phase and size exclusion chromatography) have found all HPLC
separation techniques are good for high precision quantification of free ovalbumin. The reverse
phase HPLC method is a robust method, as shown here and in previous studies [38]. The results
from our studies show the RP-HPLC (reverse phase method) is a good quantification method for
protein, with an LOQ of less than 10 µg/mL determined. Equally, the HPLC-ELSD quantification
performed to a high degree of accuracy (>90%) and is the most sensitive method (LOQ of 2.33 µg/mL).
Unlike the BCA assay method, solubilisation of the liposomes is not necessary, due to the vaporisation
of the analytes in HPLC-ELSD, and that quantification of lipids and proteins may be undertaken
simultaneously. Comparison of the three quantification techniques has shown all three methods
(RP-HPLC, HPLC-ELSD, BCA assay) are agreeable. The ANOVA results show there is no significant
difference between the three techniques when measuring OVA encapsulation. However, there is
an inherent error associated with measuring variables (such as encapsulation efficiency); neither
gives an absolute correct measurement. Linear regression models are not favoured when comparing
methods, as they study the linear relationship between measurements [39]. As a result, the Bland and
Altman approach was used to measure the comparability between the three analytical techniques.
It is based on the agreement between methods by studying the mean difference and setting limits
of agreement [40,41]. The data points are plotted as a scatter plot and are within agreement with
95% of the data being within ± 2 standard deviations [41,42]. This is observed irrespective of the
formulation investigated (DSPC:Chol, DSPC:Chol:PS and DSPC:Chol:DOTAP), thus highlighting
good agreeability between the three analytical techniques. These results highlight the versatility of
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all three techniques to quantify protein loading in neutral, anionic and cationic charged liposomes.
Whilst pegylated liposomes were not tested within this study, the above outlined methods will also
be applicable to such formulations. Furthermore, although all three methods can be used for protein
quantification, the technique and separation method will depend on the protein and formulation to be
investigated [38,43].
5. Conclusions
The three analytical techniques (BCA assays, RP-HPLC and HPLC-ELSD) were compared for their
ability to determine OVA concentration. The results are comparable, with all techniques able to detect
and quantify OVA to a high degree of sensitivity. HPLC techniques are preferred for larger screening
as the processing time is quicker. In particular, HPLC-ELSD can be fine-tuned by adjusting the gain,
with samples not requiring solubilisation, and thus, may be the most ideal for the quantification of
protein loaded in liposomes. Should solubilisation be required, the outlined method was shown to
be effective for neutral, anionic and cationic liposomes. Depending on the protein encapsulated, the
HPLC methods may need optimising depending on the protein attributes. The final analytical choice,
however, will also be dictated by time and the resources available.
Author Contributions: Conceptualization, M.T.H., N.F., Y.P.; methodology, M.T.H., N.F., Y.P.; validation M.T.H.,
N.F., Y.P.; formal analysis, M.T.H., N.F., Y.P.; investigation, M.T.H., N.F.; resources, Y.P.; data curation, M.T.H., N.F.;
writing—original draft preparation, M.T.H., N.F.; writing—review and editing, M.T.H., N.F., Y.P.; visualisation
M.T.H., N.F., Y.P.; supervision, Y.P.; project administration, Y.P.; funding acquisition, Y.P. Both M.T.H. and N.F.
contributed equally to this work.
Funding: This work was part funded by the EPSRC Centre for Innovative Manufacturing in Emergent Therapies
(EPSRC) (EP/I033270/1) and the University of Strathclyde.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Carter, P.J. Introduction to current and future protein therapeutics: A protein engineering perspective.
Exp. Cell Res. 2011, 317, 1261–1269. [CrossRef] [PubMed]
2. Leader, B.; Baca, Q.J.; Golan, D.E. Protein therapeutics: A summary and pharmacological classification.
Nat. Rev. Drug Discov. 2008, 7, 21. [CrossRef] [PubMed]
3. Gupta, S.; Jain, A.; Chakraborty, M.; Sahni, J.K.; Ali, J.; Dang, S. Oral delivery of therapeutic proteins and
peptides: A review on recent developments. Drug Deliv. 2013, 20, 237–246. [CrossRef] [PubMed]
4. Wilkinson, A.; Lattmann, E.; Roces, C.B.; Pedersen, G.K.; Christensen, D.; Perrie, Y. Lipid conjugation of TLR7
agonist Resiquimod ensures co-delivery with the liposomal Cationic Adjuvant Formulation 01 (CAF01) but
does not enhance immunopotentiation compared to non-conjugated Resiquimod+ CAF01. J. Control. Release
2018, 291, 1–10. [CrossRef] [PubMed]
5. Marin, M.I.; Benseny-Cases, N.; Camacho, M.; Perrie, Y.; Suades, J.; Barnadas, R. Metallosomes for biomedical
applications by mixing molybdenum carbonyl metallosurfactants and phospholipids. Dalton Trans. 2018, 47,
14293–14303. [CrossRef]
6. Gadd, A.J.; Castelletto, V.; Kabova, E.; Shankland, K.; Perrie, Y.; Hamley, I.; Cobb, A.J.; Greco, F.;
Edwards, A.D. High potency of lipid conjugated TLR7 agonist requires nanoparticulate or liposomal
formulation. Eur. J. Pharm. Sci. 2018, 123, 268–276. [CrossRef]
7. Joshi, S.; Hussain, M.T.; Roces, C.B.; Anderluzzi, G.; Kastner, E.; Salmaso, S.; Kirby, D.J.; Perrie, Y.
Microfluidics based manufacture of liposomes simultaneously entrapping hydrophilic and lipophilic drugs.
Int. J. Pharm. 2016, 514, 160–168. [CrossRef]
8. Abraham, S.A.; Waterhouse, D.N.; Mayer, L.D.; Cullis, P.R.; Madden, T.D.; Bally, M.B. The Liposomal
Formulation of Doxorubicin. In Methods in Enzymology; Academic Press: Cambridge, MA, USA, 2005;
Volume 391, pp. 71–97.
9. Jahn, A.; Vreeland, W.N.; DeVoe, D.L.; Locascio, L.E.; Gaitan, M. Microfluidic Directed Formation of
Liposomes of Controlled Size. Langmuir 2007, 23, 6289–6293. [CrossRef]
Pharmaceutics 2019, 11, 39 15 of 16
10. Kastner, E.; Kaur, R.; Lowry, D.; Moghaddam, B.; Wilkinson, A.; Perrie, Y. High-throughput manufacturing
of size-tuned liposomes by a new microfluidics method using enhanced statistical tools for characterization.
Int. J. Pharm. 2014, 477, 361–368. [CrossRef]
11. Hare, J.I.; Lammers, T.; Ashford, M.B.; Puri, S.; Storm, G.; Barry, S.T. Challenges and strategies in anti-cancer
nanomedicine development: An industry perspective. Adv. Drug Deliv. Rev. 2017, 108, 25–38. [CrossRef]
12. Perrie, Y.; Mohammed, A.R.; Kirby, D.J.; McNeil, S.E.; Bramwell, V.W. Vaccine adjuvant systems: Enhancing
the efficacy of sub-unit protein antigens. Int. J. Pharm. 2008, 364, 272–280. [CrossRef] [PubMed]
13. Haidar, Z.S.; Hamdy, R.C.; Tabrizian, M. Protein release kinetics for core–shell hybrid nanoparticles based
on the layer-by-layer assembly of alginate and chitosan on liposomes. Biomaterials 2008, 29, 1207–1215.
[CrossRef] [PubMed]
14. Huang, J.-H.; Wu, C.-W.; Lien, S.-P.; Leng, C.-H.; Hsiao, K.-N.; Liu, S.-J.; Chen, H.-W.; Siu, L.-K.; Chong, P.
Recombinant lipoprotein-based vaccine candidates against C. difficile infections. J. Biomed. Sci. 2015, 22, 65.
[CrossRef] [PubMed]
15. Li, N.; Peng, L.-H.; Chen, X.; Nakagawa, S.; Gao, J.-Q. Effective transcutaneous immunization by antigen-loaded
flexible liposome in vivo. Int. J. Nanomed. 2011, 6, 3241–3250.
16. Christine Lutsiak, M.E.; Kwon, G.; Samuel, J. Analysis of peptide and lipopeptide content in liposomes.
J. Pharm. Pharm Sci. 2002, 5, 279–284.
17. Xu, X.; Costa, A.; Burgess, D.J. Protein Encapsulation in Unilamellar Liposomes: High Encapsulation
Efficiency and A Novel Technique to Assess Lipid-Protein Interaction. Pharm. Res. 2012, 29, 1919–1931.
[CrossRef]
18. Henriksen-Lacey, M.; Bramwell, V.W.; Christensen, D.; Agger, E.-M.; Andersen, P.; Perrie, Y. Liposomes
based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble
antigen. J. Control. Release 2010, 142, 180–186. [CrossRef]
19. Schiltz, E.; Schnackerz, K.; Gracy, R. Comparison of ninhydrin, fluorescamine, and o-phthaldialdehyde for
the detection of amino acids and peptides and their effects on the recovery and composition of peptides
from thin-layer fingerprints. Anal. Biochem. 1977, 79, 33–41. [CrossRef]
20. Walker, J.M. The Bicinchoninic Acid (BCA) Assay for Protein Quantitation. In The Protein Protocols Handbook;
Walker, J.M., Ed.; Humana Press: Totowa, NJ, USA, 1996; pp. 11–14.
21. Awade, A.C.; Efstathiou, T. Comparison of three liquid chromatographic methods for egg-white protein
analysis. J. Chromatogr. B Biomed. Sci. Appl. 1999, 723, 69–74. [CrossRef]
22. Umrethia, M.; Kett, V.L.; Andrews, G.P.; Malcolm, R.K.; Woolfson, A.D. Selection of an analytical method
for evaluating bovine serum albumin concentrations in pharmaceutical polymeric formulations. J. Pharm.
Biomed. Anal. 2010, 51, 1175–1179. [CrossRef]
23. Bartolomeo, M.P.; Maisano, F. Validation of a reversed-phase HPLC method for quantitative amino acid
analysis. J. Biomol. Tech. 2006, 17, 131–137. [PubMed]
24. Vervoort, N.; Daemen, D.; Török, G. Performance evaluation of evaporative light scattering detection and
charged aerosol detection in reversed phase liquid chromatography. J. Chromatogr. A 2008, 1189, 92–100.
[CrossRef] [PubMed]
25. Roces, C.B.; Kastner, E.; Stone, P.; Lowry, D.; Perrie, Y. Rapid Quantification and Validation of Lipid
Concentrations within Liposomes. Pharmaceutics 2016, 8, 29. [CrossRef] [PubMed]
26. Douville, V.; Lodi, A.; Miller, J.; Nicolas, A.; Clarot, I.; Prilleux, B.; Megoulas, N.; Koupparis, M. Evaporative
light scattering detection (ELSD): A tool for improved quality control of drug substances. Pharmeur. Sci. Notes
2006, 2006, 9–15.
27. Liu, W.; Ye, A.; Liu, W.; Liu, C.; Han, J.; Singh, H. Behaviour of liposomes loaded with bovine serum albumin
during in vitro digestion. Food Chem. 2015, 175, 16–24. [CrossRef] [PubMed]
28. Colletier, J.-P.; Chaize, B.; Winterhalter, M.; Fournier, D. Protein encapsulation in liposomes: Efficiency
depends on interactions between protein and phospholipid bilayer. BMC Biotechnol. 2002, 2, 9. [CrossRef]
29. Huang, Y.-Y.; Wang, C.-H. Pulmonary delivery of insulin by liposomal carriers. J. Control. Release 2006, 113,
9–14. [CrossRef] [PubMed]
30. Hadjidemetriou, M.; McAdam, S.; Garner, G.; Thackeray, C.; Knight, D.; Smith, D.; Al-Ahmady, Z.;
Mazza, M.; Rogan, J.; Clamp, A. The Human In Vivo Biomolecule Corona onto PEGylated Liposomes:
A Proof-of-Concept Clinical Study. Adv. Mater. 2018. [CrossRef]
Pharmaceutics 2019, 11, 39 16 of 16
31. Kaminski, G.A.; Sierakowski, M.R.; Pontarolo, R.; dos Santos, L.A.; de Freitas, R.A. Layer-by-layer
polysaccharide-coated liposomes for sustained delivery of epidermal growth factor. Carbohydr. Polym.
2016, 140, 129–135. [CrossRef]
32. Cao, H.; Dan, Z.; He, X.; Zhang, Z.; Yu, H.; Yin, Q.; Li, Y. Liposomes Coated with Isolated Macrophage
Membrane Can Target Lung Metastasis of Breast Cancer. ACS Nano 2016, 10, 7738–7748. [CrossRef]
33. Guideline, I.H.T. Validation of Analytical Procedures: Text and Methodology Q2 (R1). Available
online: https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/
Step4/Q2_R1__Guideline.pdf (accessed on 18 Januray 2019)
34. Long, G.L.; Winefordner, J.D. Limit of detection. A closer look at the IUPAC definition. Anal. Chem. 1983, 55,
712A–724A.
35. Fatouros, D.G.; Antimisiaris, S.G. Effect of amphiphilic drugs on the stability and zeta-potential of their
liposome formulations: A study with prednisolone, diazepam, and griseofulvin. J. Colloid Interface Sci. 2002,
251, 271–277. [CrossRef] [PubMed]
36. Kessler, R.J.; Fanestil, D.D. Interference by lipids in the determination of protein using bicinchoninic acid.
Anal. Biochem. 1986, 159, 138–142. [CrossRef]
37. Tipton, E.; Shuster, J. A framework for the meta-analysis of Bland–Altman studies based on a limits of
agreement approach. Stat. Med. 2017, 36, 3621–3635. [CrossRef] [PubMed]
38. Grotefend, S.; Kaminski, L.; Wroblewitz, S.; Deeb, S.E.; Kühn, N.; Reichl, S.; Limberger, M.; Watt, S.; Wätzig, H.
Protein quantitation using various modes of high performance liquid chromatography. J. Pharm. Biomed. Anal.
2012, 71, 127–138. [CrossRef] [PubMed]
39. Twomey, P.; Kroll, M. How to use linear regression and correlation in quantitative method comparison
studies. Int. J. Clin. Pract. 2008, 62, 529–538. [CrossRef] [PubMed]
40. Eksborg, S. Evaluation of method-comparison data. Clin. Chem. 1981, 27, 1311–1312. [PubMed]
41. Altman, D.G.; Bland, J.M. Measurement in medicine: The analysis of method comparison studies. Statistician
1983, 32, 307–317. [CrossRef]
42. Giavarina, D. Understanding bland altman analysis. Biochem. Medica Biochem. Medica 2015, 25, 141–151.
[CrossRef]
43. Megoulas, N.C.; Koupparis, M.A. Twenty Years of Evaporative Light Scattering Detection. Crit. Rev.
Anal. Chem. 2005, 35, 301–316. [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
